B Cell News and Research

RSS

Viral Genetics issued patent for novel cancer therapies

Biotechnology firm Viral Genetics, Inc. has been issued a patent for novel cancer therapies. The patent protects cancer drugs that have been tested in pre-clinical research studies in mice. Issued on March 31, 2009, the U.S. Patent Number is: 7,510,710. Additional patents directed at generic classes of the drugs are still pending.

22 May 2009

Cancer drugs erlotinib and gefitinib might treat alcoholism

A class of drugs already approved as cancer treatments might also help to beat alcohol addiction. That's the conclusion of a discovery in flies of a gene, dubbed happyhour, that has an important and previously unknown role in controlling the insects' response to alcohol.

22 May 2009

Discovery of a fundamental mechanism for cell organization

Scientists have discovered that cells use a very simple phase transition -- similar to water vapor condensing into dew -- to assemble and localize subcellular structures that are involved in formation of the embryo.

22 May 2009

Discovery of gene that controls sugar production, implications for diabetes

Scientists in Sydney and Boston believe they may have identified a gene that controls abnormal production of sugar in the liver, a very troublesome problem for people with diabetes.

22 May 2009

Researchers discuss combined approach to maximize benefits and minimize risks of stem cell therapy

Once placed into a patient's body, stem cells intended to treat or cure a disease could end up wreaking havoc simply because they are no longer under the control of the clinician.

22 May 2009

Research details function of key protein in cancer spread

Research led by David Worthylake, PhD, Assistant Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, may help lay the groundwork for the development of a compound to prevent the spread of cancer. The research will be published in the May 29, 2009 issue of the Journal of Biological Chemistry.

22 May 2009

Protein discovery provides new targets for drugs that could extend the healthy years of life

A protein that plays a key role in tumor formation, oxygen metabolism and inflammation is involved in a pathway that extends lifespan by dietary restriction.

22 May 2009

Tuberculosis can evade immune response

Current research suggests that Mycobacterium tuberculosis can evade the immune response. The related report by Rahman et al, "Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory T cells in the granulomatous lesions," appears in the June 2009 issue of The American Journal of Pathology.

22 May 2009

Research suggests role of low vitamin D in cancer

In studying the preventive effects of vitamin D, researchers at the Moores Cancer Center at the University of California, San Diego, have proposed a new model of cancer development that hinges on a loss of cancer cells' ability to stick together. The model, dubbed DINOMIT, differs substantially from the current model of cancer development, which suggests genetic mutations as the earliest driving forces behind cancer.

22 May 2009

Novel method stimulates growth of new neurons in adult brain

University at Buffalo researchers have identified a new mechanism that plays a central role in adult brain stem cell development and prompts brain stem cells to differentiate into neurons.

21 May 2009

Toddler’s mysterious meningitis trumps cancer threat

Brooklynn Spencer's mother Samantha knew something wasn't right. The 8 month old had the flu recently, but it had been four weeks. She should have been better. The Elmira mother of four pushed for blood tests in early October 2007. A few hours later, there was a knock at the door.

21 May 2009

A new slow-release hydrogen sulfide donating molecule may hold the key to the development of new anti-inflammatory drugs

Researchers from the Peninsula Medical School in Exeter have synthesized a new molecule which releases hydrogen sulfide (H2S) - the gas that gives rotten eggs their characteristic smell and which has recently been found to be produced naturally in the body - and discovered that it could in time lead to a range of new, safer and effective anti-inflammatory drugs for human use.

20 May 2009

People with Down syndrome may have more cancer-protective genes

Most cancers are rare in people with Down syndrome, whose overall cancer mortality is below 10 percent of that in the general population. Since they have an extra copy of chromosome 21, it's been proposed that people with Down syndrome may be getting an extra dose of one or more cancer-protective genes.

20 May 2009

Junk DNA may not be so ‘junky’ after all

Scientists have called it "junk DNA." They have long been perplexed by these extensive strands of genetic material that dominate the genome but seem to lack specific functions. Why would nature force the genome to carry so much excess baggage?

20 May 2009

Vitamin D may halt lung function decline in asthma and COPD

Vitamin D may slow the progressive decline in the ability to breathe that can occur in people with asthma as a result of human airway smooth muscle (HASM) proliferation, according to researchers at the University of Pennsylvania.

20 May 2009

Arsenic exposure linked to influenza A (H1N1) susceptibility

The ability to mount an immune response to influenza A (H1N1) infection is significantly compromised by a low level of arsenic exposure that commonly occurs through drinking contaminated well water, scientists at the Marine Biological Laboratory (MBL) and Dartmouth Medical School have found.

20 May 2009

Nanoparticles used to stimulate growth of new neurons in adult brain

University at Buffalo researchers have identified a new mechanism that plays a central role in adult brain stem cell development and prompts brain stem cells to differentiate into neurons.

20 May 2009

NIH to develop therapeutics for rare and neglected diseases

The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.

20 May 2009

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL).

20 May 2009

Researchers develop questions to determine risk of HIV/AIDS drug resistance

Researchers from the Makerere University hospital in Uganda, the U.S. and Belgium have developed a formula, based on a set of questions, for determining HIV-positive people's risk of treatment failure and drug resistance, according to a study recently published in the Journal of the International AIDS Society, the New York Times reports.

19 May 2009